Homozygotes for homocystinuria due to cystathionine synthase (CS) deficiency accumulate homocysteine and methionine in their blood and tissues. High-dose pyridoxin, folic acid, vitamin B12, or betaine are therapeutical options to lower the elevated homocysteine concentration. These compounds stimulate the transsulfuration or remethylation of homocysteine. Despite such treatment, elevated blood homocysteine concentrations may persist in many homocystinurics. Therefore, it is warranted to study alternative regimen to reduce the blood homocysteine concentration in homocystinurics. Apart from entering the transsulfuration pathway, methionine can be catabolized via the transamination pathway, by conversion into 4-methylthio-2-oxobutyrate (MTOB), followed by oxidative decarboxylation of MTOB to 3-methylthiopropionate. Thiamine pyrophosphate, the active form of thiamine, is a cofactor of the supposed rate-limiting oxidative decarboxylation in the transamination of methionine. The effect of thiamine administered in 2 or 3 daily doses of 25 mg orally, was studied in nine homozygote CS deficient patients. Methionine levels decreased in 6 out of 9 patients. In 8 out of 9 patients, however, the levels of plasma homocysteine remained virtually unchanged, as did the serum transamination metabolites in alt patients. We conclude that vitamin B 1 cannot be used as an additional homocysteine-lowering treatment in most homozygotes for homocystinuria.
Introduction
Patients with classic homocystinuria due to cystathion ine synthase (CS) deficiency accumulate homocysteine and in their blood and tissues. The disease is clinically characterized by arteriosclerosis, thromboem bolism, eye-lens luxation, marfanoid features, osteoporo sis, and mental retardation. Therapy is based on reduction of the hyperhomocysteinemia by stimulation of residual CS activity by high levels of the cofactor pyridoxal-5'-phosphate [1] . About 60% of these patients respond to pyridoxine. In poor or non-pyridoxine responsive patients, treatment can be extended with folic acid, vitamin B 12 or betaine supplementation, which enhances the homo cysteine remethylation (Fig. 1) tion, dietary methionine restriction may be mandatory to reduce the blood homocysteine concentration. Despite this variety of therapeutical options, severely elevated homo cysteine concentrations may persist in homocystinuria [2, 3] . It is wart for additional possibilities to reduce the blood homocysteine concentration in homocystinurics. Apart from entering the transsulfuration pathway, me thionine can also be degraded via the transamination path way by conversion into 4 -methylthio-2~oxobutyrate (MTOB), followed by oxidative decarboxylation of MTOB to 3-methylthiopropionate (Fig. I) [4] . In the latter reaction thiamine pyrophosphate, the active form of thiamine, is a cofactor.
We previously demonstrated in an in vitro study that thiamine pyrophosphate stimulates the degradation of me thionine via the transamination pathway in rat liver ho- 1317 (1996) [101] [102] [103] [104] mogenates [5] , The same result was obtained in human cysteine-lowering treatment which was also twice daily, liver homogenates (Blom; unpublished results). In this Patients 3 and 4 are brothers, as well as patients 6 and 7 study, the methionine and homocysteine-lowering effect of (Table 1) . thiamine (vitamin B l) was tested in nine homozygote CS deficient patients.
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Methionine and homocysteine assay techniques
Materials and methods
Homozygotes fo r homocystinuria due to CS deficiency
The criteria for selection of homozygotes for homo cystinuria to enter this study were: regularly visiting our hospital, known with good compliance to their homo cysteine-lowering treatment, prolonged elevated homocysteine levels in blood despite homocysteinelowering treatment for at least 2 yr, and at least 14 yr of age. Homozygosity for homocystinuria in nine patients was proven by hypermethioninemia, severe hyperhomocysteinemia as well as a near to absent CS activity in cultured skin fibroblasts [3] . None of them were on a regimen of methionine restriction, except one (patient number 9; Table  1 ). In addition to their conventional homocysteine-lowering treatment, six patients received 25 mg of thiamine hydro chloride for 6 weeks three times daily and three patients twice daily (Table 1: patient number 2 , 6 and 7). The latter three patients received only in total 50 mg thiamine hydro chloride conforming with their conventional homoFasting EDTA venous blood samples were centrifuged immediately after puncture and stored at -20°C until analysis. Methionine concentrations were determined on a LC 2 0 0 0 amino acid analyser (Biotronik Wissenschaftliche Geräte, Munich, Germany) [6 ] . The total homocysteine concentrations (free plus protein-bound) were measured by a technique based on high-performance liquid chromatog raphy (HPLC) and fluorescent detection [7] .
Transamination metabolites assay techniques
The degradation of methionine via the transamination pathway before and after treatment was studied by quan tification in serum by the sum of the transamination metabolites 4-methylthio-2-oxobutyrate and the mixed disulfides of methanethiol (R-S-S-CH3). The blood con centrations of these metabolites are low and near the detection limit, and because of reasons of accuracy, we prefer to measure the total sum of these transamination metabolites. This technique is based on gas chromatogra phy (Packard type 429; Packard-Becker, Delft, the Nether lands), supplied with a sulfur-specific flame-photometric
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Vitamin B l measurements
Total thiamine concentrations were determined by a modified procedure of the reversed-phase ion-pair HPLC technique described by Wielders and Mink [11] . Whole blood specimens are deproteinized with perchloric acid, followed by acid phosphatase hydrolysis of thiamine tri-, di-and monophosphate to thiamine, and derivatisation of total with K,Fe(CN)f. to thiochrome which is quantified fluorimetrically at excita tion and emission wave lengths of 364 nm and 462 run, respectively. Due to preparation steps prior to HPLC, total analysis time of a blood s takes approx. 2 0 h the HPLC run itself, requires less than 10 min. The limit of detection of the technique is 2 .3 nmol thiamine/1 and excellent linear standard dose-responses is obtained up to 400 nmol/1. At mean concentrations of 123 nmol/1, the precision of the technique revealed intra-assay and interassay coefficients of variation of 4.8% (9 assay runs) 6 .8 % (1 0 0 consecutive assay runs), res 2.5. Statistical analysis as mean ± SD. The vitamin Bl plasma concentration in the homozy gotes for homocystinuria increased from 123 ± 30 (mean ± SD) nmol/1 (n -7) before thiamine treatment to 207 ± 38 nmol/1 (n = 7) after six weeks of thiamine treatment 1). The fasting blood concentration from 194 ± 127 /xrnol/1 (mean ± SD) thiamine treatment to 128 ± 9 4 iim ol/l after thiamine vs. 83 ± 22 /¿mol/1. Only one out of treated patients showed a considerable of the concentration simultaneously with a major decrease of the methionine level (Table 1 , patient number 1). Currently, this patient continues the vitamin Bl supple-3 yr basal total mi nation is now as of transamination concentration at low as 34 ¡jlmol/1, metabolites after thiamine did not increase in In fact, these levels remained low or undetectable in six
with a decrease of the ; concentration since the start with thiamine the level of the transamination metabo-mia due to methionine adenosyl transferase (MAT) defilites of methionine were not elevated during thiamine ciency do degrade quantitative amounts of methionine via administration. But, the levels of these metabolites may the transamination pathway [12, 16] , whereas patients with hypermethioninemia due to cystathionine synthase (CS) deficiency do not, despite elevated methionine levels [6] . The functional impairment of methionine transamination may be due to the different biochemical level of the blockade in the methionine metabolism or due to the treatment of CS deficient patients by pharmacological amounts of vitamins, in particulary pyridoxine [6] . The present study was performed because of the theoretical possibility to lower homocysteine concentrations by en hancement of methionine degradation via the transaminahave remained unchanged despite an increased methionine degradation through the transamination pathway. Studies using stable isotopes of methionine could clarify this mat ter.
In conclusion, orally administered thiamine lowered the homocysteine level in only one out of the nine homo cystinuric patients studied despite the reduction of the methionine concentration in most patients. Therefore, vita min B 1 appears to be only a minor alternative option for homocysteine-lowering treatment next to vitamin B6 , B12, folic acid, and betaine in homozygotes for homocystinuria. tion pathway in CS deficient patients.
Previous in vitro studies with rats [5] and human homogenates [Blom H, unpublished data] have shown that thiamine pyrophosphate stimulated the methionine degra dation via the transamination pathway 2.5 fold. This active form of thiamine is a cofactor of the branched-chain
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This study was supported by a grant from The Nether lands Heart Foundation (No. 89.121). 2 -oxo-acid dehydrogenase complex which catalyses the oxydative decarboxylation of 4-methylthio~2-oxobutyrate into 3-methyl thiopropionate [13, 14] . This decarboxylation References is supposed to be the rate-limiting reaction in the transami nation of methionine [4] . cysteine and serum transamination metabolites, despite the observed reduction of their methionine concentrations. Very recently, it has been reported that transamination in hypermethioninemic children is abnormally elevated only when plasma methionine levels exceeded 300 or 350 ¡xM [15, 16] . In the present study, only patient number 9 (Table  1) has a methionine level above this methionine level, and indeed, his transamination metabolites were higher than in the other 8 investigated homozygotes for homocystinuria, but still much lower than those of MAT deficient patients with comparable methionine levels [6, 16] . But even his serum transamination metabolites concentration did not increase after the supplementation of thiamine. We have no straightforward explanation for the reduc tion of the methionine concentration in most of the homocystinuric patients due to thiamine supplementation. The flux of methionine degradation through the transamination pathway can be decreased by glutamine, glutamic acid, of 4-methyl thio-2-alanine or leucine in the oxobutyrate [17] . Thiamine is involved as a cofactor in the oxydative decarboxylation in the of many amino acids, including the four mentioned above. Theoret ically, thiamine administration may decrease the levels of glutamine, glutamic acid, alanine and leucine, and indi rectly stimulate methionine degradation via its transamina tion pathway. However, the serum transamination metabo-
